Published on:July 2022
Indian Journal of Pharmacy Practice, 2022; 15(3):162-166
Review Article | doi:10.5530/ijopp.15.3.31


Shangavi Vellingiri, Sharmila Nirojini Palanisamy, Nithyakala Pushpanathan, Nithya Raju, Malarvizhi Palanivel, Vaishnavi Devi Chinraj

Department of Pharmacy Practice, Swamy Vivekanandha College of Pharmacy, Tirucehngode, Namakkal, Tamil Nadu, INDI


Multidrug-resistant Gram-negative bacteria have become more common in India, and they are linked to lengthier hospital stays. Colistin (Polymyxin E) is a clinically employed antibacterial inactive prodrug of colistin sulfate and colistimethate sodium (CMS). Colistin is an antibiotic used to treat infections caused by MDR Gram-negative bacteria as a last resort. The outer membrane of gram-negative bacteria is bound by the colistin mechanism. Polymyxin E and polymyxin B are commonly utilized in practice. Recent clinical trial methods for the use of colistin with other antibiotics have shown that it can boost antibacterial efficacy, and it will be a “last-line” therapy against MDR gramnegative organisms in the twenty-first century. Clinical uses, dosing considerations, range of efficacy, toxicity level, co-administration with other antibiotics, and prospects are all revealed in the review.

Keywords: Antibiotic, Polymyxin, Colistin Methane Sulfonate, MDR- Gram-negative bacteria, Last-line therapy